Caroline Ruetsch-Chelli

Caroline Ruetsch-Chelli

Auto-generated profile, based on publicly available information

Caroline Ruetsch-Chelli

Université Côte d'Azur, INSERM, C3M, Team Microenvironment, Signalling and Cancer, Nice, France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2024 in Journal of Medical Internet Research
Verified
Journal Article
Open access
MCMikaël Chelli
Mikaël Chelli
JDJules Descamps
Jules Descamps
VLVincent Lavoué
Vincent Lavoué
CTChristophe Trojani
Christophe Trojani
MAMichel Azar
Michel Azar
CRCaroline Ruetsch-Chelli
Caroline Ruetsch-Chelli
Background: Large language models (LLMs) have raised both interest and concern in the academic community. They offer the potential for automating literature search and synthesis for systematic reviews but raise concerns regarding their reliability, as the tendency to generate unsupported (hallucinated) content persist. Objective: The aim of the study is to assess the performance of LLMs such as ChatGPT and Bard (subsequently rebranded Gemini) to produce references in the context of scientific writing. Methods: The performance of ChatGPT and Bard in replicating the results of human-conducted systematic reviews was assessed. Using systematic reviews pertaining to shoulder rotator cuff pathology, these LLMs were tested by providing the same inclusion criteria and comparing the results with original systematic review references, serving as gold standards. The study used 3 key performance metrics: recall, precision, and F1-score, alongside the hallucination rate. Papers were considered “hallucinated” if any 2 of the following information were wrong: title, first author, or year of publication. Results: In total, 11 systematic reviews across 4 fields yielded 33 prompts to LLMs (3 LLMs×11 reviews), with 471 references analyzed. Precision rates for GPT-3.5, GPT-4, and Bard were 9.4% (13/139), 13.4% (16/119), and 0% (0/104) respectively (P<.001). Recall rates were 11.9% (13/109) for GPT-3.5 and 13.7% (15/109) for GPT-4, with Bard failing to retrieve any relevant papers (P<.001). Hallucination rates stood at 39.6% (55/139) for GPT-3.5, 28.6% (34/119) for GPT-4, and 91.4% (95/104) for Bard (P<.001). Further analysis of nonhallucinated papers retrieved by GPT models revealed significant differences in identifying various criteria, such as randomized studies, participant criteria, and intervention criteria. The study also noted the geographical and open-access biases in the papers retrieved by the LLMs. Conclusions: Given their current performance, it is not recommended for LLMs to be deployed as the primary or exclusive tool for conducting systematic reviews. Any references generated by such models warrant thorough validation by researchers. The high occurrence of hallucinations in LLMs highlights the necessity for refining their training and functionality before confidently using them for rigorous academic purposes.

1 April 2021 in Neurotherapeutics
Verified
Journal Article
Closed access
PDF file
CRCaroline Ruetsch-Chelli
Caroline Ruetsch-Chelli
SBSaskia Bresch
Saskia Bresch
BSBarbara Seitz-Polski
Barbara Seitz-Polski
ARAlessandra Rosenthal
Alessandra Rosenthal
CDClaude Desnuelle
Claude Desnuelle
CLChristine Lebrun-Frenay
Christine Lebrun-Frenay

16 December 2022 in Neurology and Therapy
Verified
Journal Article
Open access
PDF file
CRCaroline Ruetsch-Chelli
Caroline Ruetsch-Chelli
DODarin T. Okuda
Darin T. Okuda
FRFanny Rocher
Fanny Rocher
STSophie Tartare-Deckert
Sophie Tartare-Deckert
Marcel DeckertMarcel Deckert
Marcel Deckert
CLChristine Lebrun-Frenay
Christine Lebrun-Frenay
Introduction S1P1 receptor modulators (S1P1-RM) are oral disease-modifying therapies (DMTs) for multiple sclerosis (MS). Several authorities have raised doubts that S1P1-RM are responsible for an increased risk of melanoma in patients with MS. We studied the in vitro effects of S1P1-RM on different melanoma cell lines to compare the effect of available S1P1-RM on the proliferation of human melanoma cells. Methods Four S1P1-RM were studied which are currently approved for managing MS, namely fingolimod (Gilenya®), siponimod (Mayzent®), ozanimod (Zeposia®), and ponesimod (Ponvory®). We tested these four drugs at different concentrations, including therapeutic doses (0.5, 1.6, 5.5, 18, and 60 µM), on human melanoma cell lines (501Mel cells, 1205LU cells, and M249R cells) to analyze in vitro cell proliferation monitored with the IncuCyte ZOOM live cell microscope (Essen Bioscience). Results At therapeutic doses, median confluence increased overall for all lineages: + 122% for ozanimod (p < 0.001), + 71% for ponesimod (p < 0.001), + 67% for siponimod (NS), and + 41% for fingolimod (p = 0.094). Ozanimod- and ponesimod-treated cells increased confluency in 501Mel, 1205LU, and M249R cell lines (p < 0.001). Conclusion These data suggest an increased proliferation of various melanoma cell lines with S1P1-RM treatments used at therapeutic concentrations for patients with MS and should raise the question of increased dermatologic surveillance.

27 September 2023 in JMIR Preprints
Verified
Preprint
Open access
MCMikaël Chelli
Mikaël Chelli
JDJules Descamps
Jules Descamps
VLVincent Lavoué
Vincent Lavoué
CTChristophe Trojani
Christophe Trojani
MAMichel Azar
Michel Azar
CRCaroline Ruetsch-Chelli
Caroline Ruetsch-Chelli
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Large language models (LLMs) have raised both interest and concern in the academic community. They offer the potential for automating literature search and synthesis for systematic reviews but raise concerns regarding their reliability, as the tendency to generate unsupported (hallucinated) content persist. Objective: The aim of the study is to assess the performance of LLMs such as ChatGPT and Bard (subsequently rebranded Gemini) to produce references in the context of scientific writing. Methods: The performance of ChatGPT and Bard in replicating the results of human-conducted systematic reviews was assessed. Using systematic reviews pertaining to shoulder rotator cuff pathology, these LLMs were tested by providing the same inclusion criteria and comparing the results with original systematic review references, serving as gold standards. The study used 3 key performance metrics: recall, precision, and F1-score, alongside the hallucination rate. Papers were considered “hallucinated” if any 2 of the following information were wrong: title, first author, or year of publication. Results: In total, 11 systematic reviews across 4 fields yielded 33 prompts to LLMs (3 LLMs×11 reviews), with 471 references analyzed. Precision rates for GPT-3.5, GPT-4, and Bard were 9.4% (13/139), 13.4% (16/119), and 0% (0/104) respectively (P<.001). Recall rates were 11.9% (13/109) for GPT-3.5 and 13.7% (15/109) for GPT-4, with Bard failing to retrieve any relevant papers (P<.001). Hallucination rates stood at 39.6% (55/139) for GPT-3.5, 28.6% (34/119) for GPT-4, and 91.4% (95/104) for Bard (P<.001). Further analysis of nonhallucinated papers retrieved by GPT models revealed significant differences in identifying various criteria, such as randomized studies, participant criteria, and intervention criteria. The study also noted the geographical and open-access biases in the papers retrieved by the LLMs. Conclusions: Given their current performance, it is not recommended for LLMs to be deployed as the primary or exclusive tool for conducting systematic reviews. Any references generated by such models warrant thorough validation by researchers. The high occurrence of hallucinations in LLMs highlights the necessity for refining their training and functionality before confidently using them for rigorous academic purposes.

2 April 2019 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
CRCaroline Ruetsch
Caroline Ruetsch
JRJuliette Raffort
Juliette Raffort
PPPatricia Panaia-Ferrari
Patricia Panaia-Ferrari
CDCélia Deconde
Célia Deconde
CCCeline Caruba-Bafghi
Celine Caruba-Bafghi
GCGuilia Chinetti
Guilia Chinetti
Normal haemoglobin is a tetramer molecule, consisting of two α and β haemoglobin chains. Haemoglobinopathies occur when abnormalities in these proteins are present. More than 1000 naturally occurring human haemoglobin variants with single amino acid substitution throughout the molecule have been identified and can be discovered through their clinical and biological manifestations. Here, we report the case of a 60-year-old woman for whom no oximetry results were obtained during blood gas analysis (BGA) and the values of oxygen saturation obtained from pulse oximetry (73%) and co-oximetry (90%) differed. Haemoglobin analysis demonstrated the presence of a variant in the alpha chain. Clinical history of the patient and her family revealed they carry a haemoglobin variant (Titusville type), thus representing the first French family case reported. Those results raised the question whether the presence of this variant could be the cause of the errors encountered during BGA.

1 January 2022 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
MCMarion Cremoni
Marion Cremoni
JAJonathan Allouche
Jonathan Allouche
DGDaisy Graça
Daisy Graça
KZKevin Zorzi
Kevin Zorzi
CFCéline Fernandez
Céline Fernandez
BSBarbara Seitz-Polski
Barbara Seitz-Polski
Background: The SARS-CoV-2 infection has spread rapidly around the world causing millions of deaths. Several treatments can reduce mortality and hospitalization. However, their efficacy depends on the choice of the molecule and the precise timing of its administration to ensure viral clearance and avoid a deleterious inflammatory response. Methods: In 115 subjects at an early stage of SARS-CoV-2 infection (within the first five days) or within one month prior to infection, we studied IFN-γ response, assessed by a functional immunoassay, as a predictive biomarker for the risk of hospitalization. Findings: We found that individuals with IFN-γ levels below 15 IU/mL were 6·57-times more likely to be hospitalized than those with higher values (p65 years, and no vaccination were independently associated with hospitalization. Interpretation: Early analysis of the IFN-γ response in a contact or recently infected subject with SARS-CoV-2 could predict the individual risk of hospitalization and thus help the clinician to choose the appropriate treatment avoiding severe forms of infection and hospitalization. Funding: French Ministry of Health. Declaration of Interest: The authors declare no conflict of interest. Ethical Approval: The participants included in this study were extracted from three prospective monocentric cohorts at Nice University Hospital: (i) patients recruited during an infectious diseases or emergency room consultation following COVID-19 symptoms, or a contact case between March 2020 and January 2022 (CovImmune 1 study, NCT04355351); (ii) patients recruited by partner laboratories during a positive RT-PCR for SARS-CoV-2, performed in the context of suggestive symptomatology, contact case, or health pass, between August 2021 and November 2021 (CovImmune 1 study, NCT04355351); (iii) individuals monitored systematically and periodically since July 2020 as part of an epidemiological study in the context of COVID-19 (CovImmune 2 study, NCT04429594).